evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 2 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 20%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 40%Moderate 2 · 40%High 0 · 0%

Monthly pegloticase vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED

Withdrawals due to adverse events · participants with tophi in gout

Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).

1 finding from 1 review

Pegloticase every two weeks (biweekly) vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Intervention not reported

Number of participant withdrawals due to adverse events ‐ not measured · patients with acute gout

The review found no eligible studies for this question.

1 finding from 1 review